LONGMONT, Colo.--(BUSINESS WIRE)-- MicroPhage, Inc. announced today that it has received two Qualifying Therapeutic Discovery Project (QTDP) grants totaling $977,916 from the IRS. The grants, awarded as part of the Affordable Care Act, apply to small-company R&D expenditures that reduce the cost and increase the quality of healthcare in the U.S. The grants will be applied to the development of MicroPhage’s first product, the MRSA/MSSA Blood Culture Test, currently under review at the FDA.
Hospital-acquired bacterial infections currently kill over 100,000 Americans each year, including 20,000 deaths attributed to the MRSA “superbug.” Up to half of these infections are initially treated with the wrong antibiotics.
“Our technology will aid in the rapid determination of antimicrobial treatment for patients with bacterial infections,” said Drew Smith, Chief Science Officer at MicroPhage. “Armed with this information, doctors will be able to save lives and reduce the healthcare costs that are incurred by treating infections with the wrong antimicrobials.”
Based in Longmont, Colorado, privately held MicroPhage, Inc. is working to be a global leader in developing rapid, easy-to-use diagnostic products for bacterial identification and antibiotic susceptibility/resistance testing. Using its proprietary Bacteriophage Amplification platform, the Company has developed patented processes that are a platform for rapid, easy-to-use, inexpensive diagnostic and screening tests. The technology platform resembles a home pregnancy test with twin, rapid detectors. The platform does not require any instrumentation and is simple to operate, enabling microbiology testing outside of traditional laboratory settings.
Brian MacDonald, 303-652-5072
VP Marketing & Sales,
KEYWORDS: United States North America Colorado
INDUSTRY KEYWORDS: Health Hospitals Infectious Diseases Other Health FDA General Health